...
首页> 外文期刊>The breast journal >Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation
【24h】

Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation

机译:淋巴间隙浸润不是保乳手术和放疗治疗的早期乳腺癌结局的独立预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

To study the prognostic importance of lymphovascular invasion (LVI) in early stage breast cancer after conservative surgery and radiation. From 2/80 to 8/07, 1,478 patients were treated with breast-conserving surgery and radiation with or without systemic therapy. Study eligibility included breast conservation, whole breast postoperative radiation, T1-T2 disease, and known LVI status. Endpoints were 5- and 10-year actuarial outcomes for local control and survival. LVI was present in 427 patients and absent in 1,051 patients. Median follow-up was 68 and 69 months, respectively. Patients with LVI had a younger median age, were more often pre- or perimenopausal, T2, physically palpable, invasive ductal, node positive, grade 3, and treated with chemotherapy compared with patients without LVI. The 5- and 10-year local-regional recurrence was 4.5% and 9.6% with LVI compared with 1.6% and 5.6% without LVI (p = 0.01). The 5- and 10-year overall survival was 83% and 68% for LVI and 91% and 80% for no LVI, respectively (p < 0.0001). Multivariate analysis showed that LVI was not an independent predictor of local-regional control (p = 0.0697) or survival (p = 0.1184). LVI in breast cancer is found in association with other worse prognostic factors for outcome, is associated with a modest increase in local-regional recurrence, but is not an independent predictor of local-regional recurrence or survival on multivariate analysis.
机译:研究保守手术和放疗后早期乳腺癌中淋巴管浸润(LVI)的预后重要性。从2/80到8/07,有1478例患者接受了保乳手术和放疗,有或没有进行全身治疗。研究资格包括乳房保护,全乳术后放射,T1-T2疾病和已知的LVI状况。终点是5年和10年的精算结果,用于局部控制和生存。 LVI在427例患者中出现,而1,051例患者中没有。中位随访时间分别为68个月和69个月。 LVI患者的中位年龄较年轻,绝经前或围绝经期,T2,可触及的,浸润性导管,淋巴结阳性,3级,并且与没有LVI的患者相比更易接受化疗。 LVI组的5年和10年局部复发率为4.5%和9.6%,而LVI组为1.6%和5.6%(p = 0.01)。 LVI的5年和10年总生存率分别为83%和68%,无LVI的总生存期分别为91%和80%(p <0.0001)。多变量分析表明,LVI不是局部区域控制(p = 0.0697)或生存(p = 0.1184)的独立预测因子。发现乳腺癌中的LVI与其他预后更差的预后因素相关,与局部区域复发的适度增加相关,但不是多因素分析中局部区域复发或生存的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号